CRIS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Curis Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCRIS

Market Cap20.5M

Cash RunwayRunway 6-12 months

Next Catalyst2028-07-31

Public Research Snapshot

Curis Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CUDC-907 in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
CA-4948	n/a	n/a	Phase 1	Public pipeline row
First-in-Class Suppressor of TIM3	n/a	Small Molecule	n/a	Public pipeline row
Immuno-oncology	n/a	n/a	n/a	Public pipeline row
First-in-Class Suppressor of VISTA	n/a	Small Molecule	n/a	Public pipeline row
CA-170	n/a	Small Molecule	Preclinical	Public pipeline row
CUDC-907	Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations	n/a	Phase 2	Public pipeline row
CUDC-101	Tumors	n/a	Phase 1	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2028-07-31	CA-4948	Low
Corporate Update	Timing not specified	n/a	Low
Corporate Update	October 2015	CA-170	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00728793	Phase 1	COMPLETED	25	2010-04
NCT01171924	Phase 1	COMPLETED	47	2011-10
NCT02674750	Phase 2	COMPLETED	70	2019-05-28
NCT02307240	Phase 1	COMPLETED	43	2019-05-31
NCT05187182	Phase 1	RECRUITING	42	2028-07-31

Scientific Context

catalyst_type | Corporate Update
literature_publication | Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.
literature_publication | Biomarker study of pembrolizumab in patients with advanced rare cancers.
literature_publication | Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC.
literature_publication | Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Want the full CRIS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.